These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 9990471)

  • 1. Antimicrobial activity of SCH27899 (Ziracin), a novel everninomicin derivative, tested against Streptococcus spp.: disk diffusion/etest method evaluations and quality control guidelines. The Quality Control Study Group.
    Marshall SA; Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):19-25. PubMed ID: 9990471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity and spectrum of SCH27899 (Ziracin) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control. Quality Control Study Group.
    Jones RN; Marshall SA; Erwin ME
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):103-10. PubMed ID: 10354859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Quality Control Study Group.
    Jones RN; Johnson DM; Erwin ME; Beach ML; Biedenbach DJ; Pfaller MA
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):91-8. PubMed ID: 10354857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of everninomicin against clinical isolates of Enterococcus spp., Staphylococcus spp., and Streptococcus spp. tested by Etest.
    Terakubo S; Takemura H; Yamamoto H; Ikejima H; Kunishima H; Kanemitsu K; Kaku M; Shimada J
    J Infect Chemother; 2001 Dec; 7(4):263-6. PubMed ID: 11810596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines.
    Johnson DM; Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 1999 Feb; 33(2):87-91. PubMed ID: 10091031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci.
    Hope R; Chaudhry A; Adkin R; Livermore DM
    Int J Antimicrob Agents; 2013 Mar; 41(3):213-7. PubMed ID: 23298432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of retapamulin against Streptococcus pyogenes and Staphylococcus aureus evaluated by agar dilution, microdilution, E-test, and disk diffusion methodologies.
    Pankuch GA; Lin G; Hoellman DB; Good CE; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2006 May; 50(5):1727-30. PubMed ID: 16641442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.
    Fass RJ
    Antimicrob Agents Chemother; 1991 Mar; 35(3):553-9. PubMed ID: 1903912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
    Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods.
    Mohammed MJ; Marston CK; Popovic T; Weyant RS; Tenover FC
    J Clin Microbiol; 2002 Jun; 40(6):1902-7. PubMed ID: 12037041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
    Ballow CH; Jones RN; Johnson DM; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of in vitro spectra of activity of azithromycin, clarithromycin, and erythromycin tested against strains of Neisseria gonorrhoeae by reference agar dilution, disk diffusion, and Etest methods.
    Mehaffey PC; Putnam SD; Barrett MS; Jones RN
    J Clin Microbiol; 1996 Feb; 34(2):479-81. PubMed ID: 8789046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges.
    Brown SD; Traczewski MM
    Antimicrob Agents Chemother; 2010 May; 54(5):2063-9. PubMed ID: 20231392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial.
    Jones RN; Hare RS; Sabatelli FJ;
    J Antimicrob Chemother; 2001 Jan; 47(1):15-25. PubMed ID: 11152427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the results of the Etest and the method for determining minimum inhibitory concentrations in solid media for penicillin G, amoxicillin, and cefotaxime for S. pneumoniae. A multicenter study].
    Clavier B; Perrier-Gros-Claude JD; Foissaud V; Dumas M; Aubert G; Barbé G; Bland S; Boucaud Maitre Y; Boyer M; Chomarat M; Clergeau P; Delubac F; Févre D; Fuhrmann C; Gravagnat B; Letouzey MN; Mandjee A; Martelet P; Meley R; Reverdy ME; Ros A; Roure C; Sabot O; Tixier A; Thierry J
    Pathol Biol (Paris); 1998 Jun; 46(6):369-74. PubMed ID: 9769863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.
    Biedenbach DJ; Ross JE; Fritsche TR; Sader HS; Jones RN
    J Clin Microbiol; 2007 Mar; 45(3):998-1004. PubMed ID: 17215346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of agar dilution, microdilution, E-test, and disk diffusion methods for testing activity of cefditoren against Streptococcus pneumoniae.
    Kelly LM; Jacobs MR; Appelbaum PC
    J Clin Microbiol; 1999 Oct; 37(10):3296-9. PubMed ID: 10488195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility of bovine mastitis pathogens to a combination of penicillin and framycetin: development of interpretive criteria for testing by broth microdilution and disk diffusion.
    Pillar CM; Stoneburner A; Shinabarger DL; Abbeloos E; Goby L; Bradley AJ
    J Dairy Sci; 2014 Oct; 97(10):6594-607. PubMed ID: 25129497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae.
    Jorgensen JH; Swenson JM; Tenover FC; Barry A; Ferraro MJ; Murray PR; Reller LB
    J Clin Microbiol; 1996 Nov; 34(11):2679-84. PubMed ID: 8897164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.